These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33075384)

  • 1. Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.
    Fresse A; Viard D; Romani S; Gérard A; Lepelley M; Rocher F; Salem JE; Drici MD;
    Int J Cardiol; 2021 Feb; 324():255-260. PubMed ID: 33075384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
    Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
    Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QTc prolongation during antiviral therapy in two COVID-19 patients.
    Zhu S; Wang J; Wang Y; Chu J; Liu Y; Chen X; Chen X
    J Clin Pharm Ther; 2020 Oct; 45(5):1190-1193. PubMed ID: 32779770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
    Zequn Z; Yujia W; Dingding Q; Jiangfang L
    Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.
    Padilla S; Telenti G; Guillén L; García JA; García-Abellán J; Ding C; Mora A; García-Pachón E; Gutiérrez F; Masiá M;
    Int J Antimicrob Agents; 2020 Oct; 56(4):106142. PubMed ID: 32853675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.
    Andy Ko TY; Chen LS; Pang IX; Ling HS; Wong TC; Sia Tonnii LL; Koh KT
    Med J Malaysia; 2021 Mar; 76(2):125-130. PubMed ID: 33742617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance.
    Fallani E; Cevenini F; Lazzerini PE; Verdini A; Saponara S
    J Clin Pharmacol; 2022 May; 62(5):646-655. PubMed ID: 34802170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
    Echarte-Morales J; Minguito-Carazo C; Del Castillo-García S; Borrego-Rodríguez J; Rodríguez-Santamarta M; Sánchez-Muñoz E; Bergel-García R; González-Maniega C; Prieto-González S; Menéndez-Suarez P; Tundidor-Sanz E; Benito-González T; Fernández-Vázquez F
    J Electrocardiol; 2021; 64():30-35. PubMed ID: 33307378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QT Interval Monitoring with Handheld Heart Rhythm ECG Device in COVID-19 Patients.
    Minguito-Carazo C; Echarte-Morales J; Benito-González T; Del Castillo-García S; Rodríguez-Santamarta M; Sánchez-Muñoz E; Maniega CG; García-Bergel R; Menéndez-Suárez P; Prieto-González S; Palacios-Echavarren C; Borrego-Rodríguez J; Flores-Vergara G; Iglesias-Garriz I; Fernández-Vázquez F
    Glob Heart; 2021 Jun; 16(1):42. PubMed ID: 34211828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
    Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
    J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
    Arathoon E; Schneider S; Baraldi E; Lim PL; Opravil M; Van De Casteele T; Lavreys L
    Int J STD AIDS; 2013 Jan; 24(1):12-7. PubMed ID: 23440570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
    Moschini L; Loffi M; Regazzoni V; Di Tano G; Gherbesi E; Danzi GB
    Heart Vessels; 2021 Jan; 36(1):115-120. PubMed ID: 32676695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients.
    Chouchana L; Boujaafar S; Gana I; Preta LH; Regard L; Legendre P; Azoulay C; Canouï E; Zerbit J; Carlier N; Terrier B; Kernéis S; Batista R; Treluyer JM; Zheng Y; Benaboud S
    Ther Drug Monit; 2021 Feb; 43(1):131-135. PubMed ID: 33230045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
    Carron J; Sharif Z; Hussein H; Kennedy M; McAdam B; Sheahan R
    Ir J Med Sci; 2021 Feb; 190(1):403-409. PubMed ID: 32627127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
    Levy C; Lassailly G; Parmentier E; Duburcq T; Mathurin P; Poissy J
    Am J Gastroenterol; 2020 Oct; 115(10):1716-1718. PubMed ID: 32858566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis.
    Kanters S; Socias ME; Paton NI; Vitoria M; Doherty M; Ayers D; Popoff E; Chan K; Cooper DA; Wiens MO; Calmy A; Ford N; Nsanzimana S; Mills EJ
    Lancet HIV; 2017 Oct; 4(10):e433-e441. PubMed ID: 28784426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
    Ding J; Liu W; Guan H; Feng Y; Bao Y; Li H; Wang X; Zhou Z; Chen Z
    Medicine (Baltimore); 2021 Jul; 100(28):e26538. PubMed ID: 34260531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.